| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Mineralys Therapeutics, Inc.
13G/A
Amendment 3
MLYS · 603170101
|
10.1% |
2/13/2026
Event 12/31/2025
|
|||
| Catalys Pacific Fund, LP | 10.1% | ||||
| Catalys Pacific Fund GP, LP | 10.1% | ||||
| Catalys Pacific, LLC | 10.1% | ||||
| Brian Taylor Slingsby | 10.1% | ||||
|
Mineralys Therapeutics, Inc.
13G/A
Amendment 2
MLYS · 603170101
|
13.5% |
8/14/2025
Event 6/30/2025
|
|||
| Catalys Pacific Fund, LP | 13.5% | ||||
| Catalys Pacific Fund GP, LP | 13.5% | ||||
| Catalys Pacific, LLC | 13.5% | ||||
| Brian Taylor Slingsby | 13.5% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.